Evolutionary exploitation of PD-L1 expression in hormone receptor positive breast cancer
Keyword(s):
AbstractBased on clinical data from hormone positive breast cancer patients, we determined that there is a potential tradeoff between reducing tumor burden and altering metastatic potential when administering combination therapy of aromatase inhibitors and immune checkpoint inhibitors. While hormone-deprivation therapies serve to reduce tumor size in the neoadjuvant setting pre-surgery, they may induce tumors to change expression patterns towards a metastatic phenotype. We used mathematical modeling to explore how the timing of the therapies affects tumor burden and metastatic potential with an eye toward developing a dynamic prognostic score and reducing both tumor size and risk of metastasis.
2019 ◽
Vol 22
(4)
◽
pp. 474-485
◽
2006 ◽
Vol 24
(31)
◽
pp. 4956-4962
◽
2019 ◽
2020 ◽
2020 ◽
Vol 180
(2)
◽
pp. 491-501
◽
2020 ◽
Vol 184
(3)
◽
pp. 665-674